Parameter | Treatment | Baseline | Pulmonary hypertension | |
---|---|---|---|---|
 |  |  | Pre-inhalation | 5 minutes after inhalation |
REF (%) | Iloprost | 62 ± 7 | 50 ± 8* | 53 ± 8* ‡ |
 | Control | 54 ± 10 | 40 ± 11* | 37 ± 10* |
τ/RR | Iloprost | 0.08 ± 0.01 | 0.08 ± 0.01 | 0.09 ± 0.01†|
 | Control | 0.07 ± 0.01 | 0.07 ± 0.01 | 0.07 ± 0.01 |
β (ml-1) | Iloprost | 0.02 ± 0.01 | 0.02 ± 0.01 | 0.02 ± 0.01 |
 | Control | 0.02 ± 0.02 | 0.02 ± 0.01 | 0.02 ± 0.01 |
C (ml/mmHg) | Iloprost | 2.29 ± 0.49 | 1.28 ± 0.33* | 1.89 ± 0.64†|
 | Control | 2.11 ± 0.93 | 1.08 ± 0.33* | 1.11 ± 0.33* |
Emax/Ea | Iloprost | 1.12 ± 0.11 | 1.29 ± 0.29 | 1.03 ± 0.15 |
 | Control | 1.11 ± 0.46 | 1.01 ± 0.31 | 0.97 ± 0.33 |